Volume | 412,147 |
|
|||||
News | - | ||||||
Day High | 131.46 | Low High |
|||||
Day Low | 125.62 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Sarepta Therapeutics Inc New | SRPT | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
127.53 | 125.62 | 131.46 | 127.39 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,629 | 412,147 | $ 129.45 | $ 53,353,781 | - | 55.25 - 159.89 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:29:03 | 9 | $ 129.395 | USD |
Sarepta Therapeutics (SRPT) Options Flow Summary
Sarepta Therapeutics Inc New Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
12.14B | 93.86M | - | 1.24B | -535.98M | -5.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Sarepta Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SRPT Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 116.55 | 131.46 | 114.37 | 122.22 | 1,058,720 | 12.85 | 11.03% |
1 Month | 129.38 | 131.46 | 114.37 | 123.08 | 721,466 | 0.02 | 0.02% |
3 Months | 122.00 | 143.00 | 114.37 | 126.44 | 834,203 | 7.40 | 6.07% |
6 Months | 107.39 | 143.00 | 55.25 | 100.36 | 1,338,135 | 22.01 | 20.50% |
1 Year | 122.55 | 159.89 | 55.25 | 110.33 | 1,254,272 | 6.85 | 5.59% |
3 Years | 71.37 | 159.89 | 55.25 | 102.31 | 1,109,617 | 58.03 | 81.31% |
5 Years | 120.02 | 181.83 | 55.25 | 107.55 | 1,131,617 | 9.38 | 7.82% |
Sarepta Therapeutics Description
Sarepta Therapeutics is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development. |